Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

NCT07566585 is registered in ClinicalTrials.gov with BlueSphere Bio, Inc as lead sponsor.

NCT NCT07566585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07566585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Lead sponsor
BlueSphere Bio, Inc
Phase
Phase 1
Overall status
Withdrawn
Start date
April 21, 2026
Completion date
September 8, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml - acute myeloid leukemia, aml with mutated npm1, aml, adult recurrent